<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p8" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_8{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_8{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_8{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_8{left:341px;bottom:30px;}
#t5_8{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_8{left:377px;bottom:30px;}
#t7_8{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_8{left:540px;bottom:30px;}
#t9_8{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_8{left:996px;bottom:873px;letter-spacing:-0.1px;}
#tb_8{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#tc_8{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#td_8{left:1091px;bottom:28px;letter-spacing:0.24px;}
#te_8{left:36px;bottom:778px;letter-spacing:-0.12px;word-spacing:0.02px;}
#tf_8{left:36px;bottom:748px;letter-spacing:-0.15px;word-spacing:0.06px;}
#tg_8{left:36px;bottom:729px;letter-spacing:-0.09px;}
#th_8{left:41px;bottom:711px;}
#ti_8{left:58px;bottom:711px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#tj_8{left:41px;bottom:693px;}
#tk_8{left:58px;bottom:693px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#tl_8{left:58px;bottom:674px;letter-spacing:-0.08px;}
#tm_8{left:41px;bottom:656px;}
#tn_8{left:58px;bottom:656px;letter-spacing:-0.08px;word-spacing:-0.06px;}
#to_8{left:41px;bottom:638px;}
#tp_8{left:58px;bottom:638px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tq_8{left:58px;bottom:619px;letter-spacing:-0.12px;word-spacing:0.03px;}
#tr_8{left:41px;bottom:601px;}
#ts_8{left:58px;bottom:601px;letter-spacing:-0.09px;word-spacing:-0.02px;}
#tt_8{left:36px;bottom:583px;letter-spacing:-0.15px;word-spacing:0.06px;}
#tu_8{left:36px;bottom:564px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tv_8{left:47px;bottom:546px;letter-spacing:-0.1px;word-spacing:0.02px;}
#tw_8{left:36px;bottom:528px;letter-spacing:-0.15px;word-spacing:0.06px;}
#tx_8{left:36px;bottom:509px;letter-spacing:-0.1px;}
#ty_8{left:36px;bottom:491px;letter-spacing:-0.23px;word-spacing:0.14px;}
#tz_8{left:36px;bottom:473px;}
#t10_8{left:47px;bottom:473px;letter-spacing:-0.09px;word-spacing:-0.01px;}
#t11_8{left:47px;bottom:454px;letter-spacing:-0.09px;}
#t12_8{left:317px;bottom:454px;}
#t13_8{left:326px;bottom:454px;letter-spacing:-0.08px;}
#t14_8{left:520px;bottom:454px;letter-spacing:-0.08px;}
#t15_8{left:36px;bottom:436px;}
#t16_8{left:47px;bottom:436px;letter-spacing:-0.1px;word-spacing:-0.05px;}
#t17_8{left:41px;bottom:418px;}
#t18_8{left:58px;bottom:418px;letter-spacing:-0.08px;}
#t19_8{left:36px;bottom:399px;letter-spacing:-0.09px;word-spacing:-0.09px;}
#t1a_8{left:41px;bottom:381px;}
#t1b_8{left:58px;bottom:381px;letter-spacing:-0.09px;}
#t1c_8{left:41px;bottom:363px;}
#t1d_8{left:58px;bottom:363px;letter-spacing:-0.09px;word-spacing:-0.08px;}
#t1e_8{left:63px;bottom:344px;}
#t1f_8{left:76px;bottom:344px;letter-spacing:-0.09px;}
#t1g_8{left:63px;bottom:326px;}
#t1h_8{left:76px;bottom:326px;letter-spacing:-0.09px;}
#t1i_8{left:36px;bottom:308px;letter-spacing:-0.1px;word-spacing:-0.09px;}
#t1j_8{left:41px;bottom:289px;}
#t1k_8{left:58px;bottom:289px;letter-spacing:-0.08px;}
#t1l_8{left:36px;bottom:271px;letter-spacing:-0.23px;word-spacing:0.14px;}
#t1m_8{left:36px;bottom:253px;}
#t1n_8{left:47px;bottom:253px;letter-spacing:-0.09px;}
#t1o_8{left:869px;bottom:253px;letter-spacing:-0.08px;}
#t1p_8{left:36px;bottom:234px;letter-spacing:-0.09px;}
#t1q_8{left:41px;bottom:216px;}
#t1r_8{left:58px;bottom:216px;letter-spacing:-0.09px;}
#t1s_8{left:603px;bottom:216px;letter-spacing:-0.09px;}
#t1t_8{left:41px;bottom:198px;}
#t1u_8{left:58px;bottom:198px;letter-spacing:-0.09px;}
#t1v_8{left:41px;bottom:179px;}
#t1w_8{left:58px;bottom:179px;letter-spacing:-0.09px;}
#t1x_8{left:41px;bottom:161px;}
#t1y_8{left:58px;bottom:161px;letter-spacing:-0.09px;}
#t1z_8{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_8{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_8{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_8{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_8{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s4_8{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s5_8{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s6_8{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s7_8{font-size:17px;font-family:Webdings_k6;color:#000;}
.s8_8{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s9_8{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.sa_8{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sb_8{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts8" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg8Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg8" style="-webkit-user-select: none;"><object width="1210" height="935" data="8/8.svg" type="image/svg+xml" id="pdf8" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_8" class="t s0_8">NCCN Guidelines Version 4.2024 </span>
<span id="t2_8" class="t s0_8">Head and Neck Cancers </span>
<span id="t3_8" class="t s1_8">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_8" class="t s2_8">® </span>
<span id="t5_8" class="t s1_8">(NCCN </span>
<span id="t6_8" class="t s2_8">® </span>
<span id="t7_8" class="t s1_8">), All rights reserved. NCCN Guidelines </span>
<span id="t8_8" class="t s2_8">® </span>
<span id="t9_8" class="t s1_8">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_8" class="t s3_8">NCCN Guidelines Index </span>
<span id="tb_8" class="t s3_8">Table of Contents </span>
<span id="tc_8" class="t s3_8">Discussion </span>
<span id="td_8" class="t s4_8">UPDATES </span>
<span id="te_8" class="t s4_8">Updates in Version 1.2024 of the NCCN Guidelines for Head and Neck Cancers from Version 2.2023 include: </span>
<span id="tf_8" class="t s5_8">SURG-A (4 of 8) </span>
<span id="tg_8" class="t s6_8">• Margins </span>
<span id="th_8" class="t s7_8"></span><span id="ti_8" class="t s8_8" data-mappings='[[36,"fi"]]'>Bullet removed: A clear margin is deﬁned as the distance from the invasive tumor front that is 5 mm or more from the resected margin. </span>
<span id="tj_8" class="t s7_8"></span><span id="tk_8" class="t s8_8" data-mappings='[[36,"fi"]]'>Bullet removed: A close margin is deﬁned as the distance from the invasive tumor front to the resected margin that is less than 2–5 mm, depending on </span>
<span id="tl_8" class="t s6_8">the anatomic site involved. </span>
<span id="tm_8" class="t s7_8"></span><span id="tn_8" class="t s8_8" data-mappings='[[51,"fi"]]'>Bullet added: At this time there is no universal deﬁnition for what constitutes a clear/close margin. </span>
<span id="to_8" class="t s7_8"></span><span id="tp_8" class="t s8_8" data-mappings='[[75,"fl"]]'>Bullet added: Distance in mm to achieve clinically acceptable margins is inﬂuenced by tumor primary site, histology, and HPV status in oropharyngeal </span>
<span id="tq_8" class="t s6_8">cancer and following neoadjuvant therapy. </span>
<span id="tr_8" class="t s7_8"></span><span id="ts_8" class="t s8_8" data-mappings='[[50,"fi"],[86,"fi"]]'>Bullet added: The previous universally followed deﬁnition of adequate margin (5 mm in ﬁnal histopathology) has been disputed. </span>
<span id="tt_8" class="t s5_8">RAD-A (4 of 7) </span>
<span id="tu_8" class="t s6_8">• Bullet 1, sub-bullet 7, sub-sub-bullet 3 added: Hyperfractionation for locally advanced nasopharyngeal carcinoma: IMRT total dose of 65 Gy, in 54 </span>
<span id="tv_8" class="t s6_8">fractions, twice daily, with an irradiation interval of 6–8 hours </span>
<span id="tw_8" class="t s5_8">RAD-A (5 of 7) </span>
<span id="tx_8" class="t s6_8">• Newly added page </span>
<span id="ty_8" class="t s5_8">SYST-A (1 of 4) </span>
<span id="tz_8" class="t s6_8">• </span><span id="t10_8" class="t s8_8" data-mappings='[[13,"fi"]]'>Bullet 1 modiﬁed: The choice of systemic therapy should be individualized based on patient characteristics (eg, PS, goals of therapy). Next-generation </span>
<span id="t11_8" class="t s8_8" data-mappings='[[28,"fi"]]'>sequencing (NGS) genomic proﬁling</span><span id="t12_8" class="t s9_8">, </span><span id="t13_8" class="t s9_8">including testing for CPS, </span><span id="t14_8" class="t s6_8">may be considered to guide patient treatment options, including clinical trials. </span>
<span id="t15_8" class="t s6_8">• </span><span id="t16_8" class="t s8_8">Primary Systemic Therapy + Concurrent RT </span>
<span id="t17_8" class="t s7_8"></span><span id="t18_8" class="t s6_8">Useful in certain circumstances regimen added: Docetaxel (if cisplatin ineligible) </span>
<span id="t19_8" class="t s6_8">• Induction/Sequential Systemic Therapy </span>
<span id="t1a_8" class="t s7_8"></span><span id="t1b_8" class="t s6_8">Useful in certain circumstances, regimen added: Carboplatin/paclitaxel/cetuximab (category 2B) </span>
<span id="t1c_8" class="t s7_8"></span><span id="t1d_8" class="t s6_8">For newly diagnosed T3, T4a ethmoid sinus tumor </span>
<span id="t1e_8" class="t sa_8">◊ </span><span id="t1f_8" class="t s6_8">Regimen moved to here from ETHM: Etoposide/cisplatin (category 2B) </span>
<span id="t1g_8" class="t sa_8">◊ </span><span id="t1h_8" class="t s8_8" data-mappings='[[35,"fl"]]'>Regimen added: Docetaxel/cisplatin/ﬂuorouracil (category 2B). </span>
<span id="t1i_8" class="t s6_8">• Postoperative Systemic Therapy/RT </span>
<span id="t1j_8" class="t s7_8"></span><span id="t1k_8" class="t s6_8">Useful in certain circumstances, regimen added: Docetaxel (if cisplatin ineligible) </span>
<span id="t1l_8" class="t s5_8">SYST-A (2 of 4) </span>
<span id="t1m_8" class="t s6_8">• </span><span id="t1n_8" class="t s8_8" data-mappings='[[40,"fi"]]'>Other recommended regimens, regimen modiﬁed: Pembrolizumab/platinum (cisplatin or carboplatin)/paclitaxel </span><span id="t1o_8" class="t s6_8">(category 2B) </span>
<span id="t1p_8" class="t s6_8">• Useful in certain circumstances </span>
<span id="t1q_8" class="t s7_8"></span><span id="t1r_8" class="t s8_8" data-mappings='[[37,"fi"]]'>Squamous cell carcinoma, regimen modiﬁed: Cetuximab/pembrolizumab </span><span id="t1s_8" class="t s6_8">(category 2B) </span>
<span id="t1t_8" class="t s7_8"></span><span id="t1u_8" class="t s6_8">Regimen added: Paclitaxel/cetuximab </span>
<span id="t1v_8" class="t s7_8"></span><span id="t1w_8" class="t s8_8" data-mappings='[[49,"fi"]]'>Regimen added: Nivolumab/ipilimumab (CPS ≥20 and ﬁrst-line only) (category 2B) </span>
<span id="t1x_8" class="t s7_8"></span><span id="t1y_8" class="t s6_8">Regimen added: Docetaxel/cetuximab (category 2B) </span>
<span id="t1z_8" class="t sb_8">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
